Levaxin Tafla 0,05 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

levaxin tafla 0,05 mg

orifarm healthcare a/s - levothyroxinum natríum - tafla - 0,05 mg

Levaxin Tafla 0,1 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

levaxin tafla 0,1 mg

orifarm healthcare a/s - levothyroxinum natríum - tafla - 0,1 mg

Nexium Magasýruþolin tafla 20 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium magasýruþolin tafla 20 mg

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

Nexium Magasýruþolin tafla 40 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium magasýruþolin tafla 40 mg

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

Nexium Mixtúrukyrni, dreifa 10 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium mixtúrukyrni, dreifa 10 mg

grünenthal gmbh* - esomeprazolum magnesíum - mixtúrukyrni, dreifa - 10 mg

Nexium Stungulyfs-/innrennslisstofn, lausn 40 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium stungulyfs-/innrennslisstofn, lausn 40 mg

grünenthal gmbh* - esomeprazolum natríum - stungulyfs-/innrennslisstofn, lausn - 40 mg

Yesafili Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Vancomycin-MIP Innrennslisstofn, lausn 1000 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

vancomycin-mip innrennslisstofn, lausn 1000 mg

mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 1000 mg

Vancomycin-MIP Innrennslisstofn, lausn 500 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

vancomycin-mip innrennslisstofn, lausn 500 mg

mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 500 mg

CellCept Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

cellcept

roche registration gmbh - mýcófenólat mofetil - graft rejection - Ónæmisbælandi lyf - cellcept er ætlað ásamt ciclosporin og aðferðir til að fyrirbyggja bráð grætt höfnun í sjúklingar fá ósamgena skert, hjarta eða lifur ígræðslu.